"Series A to C Marketing Budgets: How to Read a SaaS Ratio in a Healthcare Board Meeting"

What you'll take away

• What SaaS Capital's private B2B SaaS survey, as summarized in 2026, actually measured
• What an agency's published stage table adds, and what it does not say about healthcare
• Why a payback median from software companies is a reference, and your closed contracts are the cycle
• The three lines a Series A to C board slide can carry without borrowing a number
• The limit: a short runway is a runway conversation, and a published ratio does not answer it

Your board wants to know why marketing costs what it costs while the company is still spending more than it collects. That is a fair question. The slide that usually arrives with it cites a percentage of annual recurring revenue from a software survey, then treats the percentage as the budget for a healthcare, biotech, device, or life sciences company.

This piece is for the founder or chief operating officer in that meeting, between Series A and Series C. The percentages below are real descriptions of other companies. They become a problem when the slide presents them as your category.

What the SaaS pages measured

Xander Marketing's 2026 writeup of SaaS Capital says the firm's survey of more than 700 private B2B SaaS companies put median marketing spend at about 8 percent of annual recurring revenue, down from around 10 percent in earlier years (Xander Marketing, 2026). That sentence is about private B2B SaaS companies. Xander is summarizing the survey. The page does not say the sample was healthcare, pharma, biotech, medical devices, or life sciences.

GrowthSpree's page, updated May 25, 2026, publishes a stage table for B2B SaaS marketing spend as a share of annual recurring revenue: Series A at 12 to 18 percent, Series B at 11 to 16 percent, Series C at 10 to 14 percent, and later stages at 8 to 12 percent (GrowthSpree, May 2026). The page is an agency's compilation. It also gives a wider band for companies that are not SaaS, 6 to 12 percent of revenue, and a still wider caution that early companies spend a higher share while they are learning a channel. Calling the Series A row a healthcare benchmark adds a claim the page does not make.

Those two pages agree that private software companies often spend a high single digit to a mid teens share of revenue, and that the share is higher earlier. They are not two censuses of your buyers. Put the SaaS Capital median on the slide only with the words "private B2B SaaS" in the same line.

Payback medians have the same limit

Aleph's October 2026 page, written with Benchmarkit from full year 2025 actuals at 342 SaaS and AI software companies, says the median company recovered its customer acquisition cost in 16 months. The top quartile did it in 6 months or fewer. The bottom quartile took 24 months or more (Aleph, CAC payback benchmarks).

That is a software sample. A 16 month median is a useful comparison when you already know your own payback and your own sales cycle. It does not tell you when your hospital, lab, or health system deals will close.

Other 2026 writeups quote different prior year figures for the same topic. When two secondary pages disagree about last year, leave last year off the slide and cite the page whose sample you can name.

Your cycle comes from your contracts

Apollo's biotech sales guide states that biotech sales cycles average 12 to 18 months (Apollo, biotech sales). The page does not show the study, the sample size, or the dates behind that sentence. A board slide that repeats it as "our cycle" is repeating a vendor guide.

Ask whoever closed the last ten contracts for the date of the first serious conversation and the date of signature. The median of those ten is your cycle until a larger set exists. If you do not have ten, say how many you have. A monthly count of new inquiries is a weak read while a deal from this quarter may still be unsigned next year.

What the slide can say

One slide, three lines. Every line names where the number came from.

Spend, labeled. "We spent $[X] on marketing in the quarter, which is [Y] percent of revenue. A SaaS Capital survey of private B2B SaaS companies, as summarized by Xander Marketing in 2026, puts the median near 8 percent of annual recurring revenue. We sell to [the buyer you actually have]. The 8 percent is a reference from another category."

Cycle, from your contracts. "On the last [N] closed contracts, the median from first serious conversation to signature was [M] months. The first date we will read revenue from this quarter's spend is [date]."

Meetings, defined. "A qualified meeting, on the definition sales and marketing both signed, is [that definition]. We report how many of those meetings were held and what each one cost. We do not promise how many the next quarter will produce."

Skip the invented monthly split. A table that divides the budget into a pipeline team, paid media, and tools looks specific, and the specificity is the problem when nobody measured those lines on your account.

The honest limit

If the company has not found a repeatable way to start conversations, acquisition math is noise. The honest topic is how fast you can test a channel, and a software median will not choose the channel.

If the cash you have lasts less than the cycle you just measured, the meeting is about runway. A percentage that would look normal at a software company can still spend you out of the company. Say that plainly. The benchmark is the start of the conversation. Your contracts and your cash set the number you defend.

This piece is a marketing operating framework, not financial advice. Budget decisions depend on your runway, your buyers, and the contracts you have actually closed. The ratios above describe the samples named in the links. They do not describe your company until you measure it.

If you're the founder or chief operating officer of a Series A to C healthcare, biotech, device, or life sciences company and the last board meeting asked why marketing costs what it costs, [book a pipeline call](/contact) and send the marketing slide plus the last ten close dates if you have them. In about ten minutes I'll tell you which line is a software reference, which line has to come from your contracts, and whether the slide can go back to the board as written. Sometimes the honest answer is that you're already fine, and we're happy to say so and hand you back your afternoon.